Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human induced pluripotent stem cell-derived retinal pigment epithelium cell sheet
- Development stage
- Unknown
- Lead developer
- VCCT
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic
01
Overview
A regenerative cell therapy consisting of a scaffold-free monolayer sheet of retinal pigment epithelial (RPE) cells differentiated from human induced pluripotent stem cells (hiPSCs). Developed by the RIKEN Center for Biosystems Dynamics Research, the therapy is designed to treat age-related macular degeneration (AMD), particularly the neovascular (wet) form, by surgically replacing damaged or lost native RPE cells. The transplanted hiPSC-RPE cells function by forming tight junctions, secreting essential growth factors (such as VEGF and PEDF), and performing phagocytosis of photoreceptor outer segments, thereby supporting retinal health and potentially stabilizing or improving vision. The therapy has been evaluated in both autologous and allogeneic clinical settings, with the first-in-human autologous transplantation performed in 2014.
- Other names
- autologous hiPSC-RPE cell sheetallogeneic hiPSC-RPE cell sheethiPSC-derived RPE cell sheet
Beyond the preview
Go deeper on human induced pluripotent stem cell-derived retinal pigment epithelium cell sheet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human induced pluripotent stem cell-derived retinal pigment epithelium cell sheet.